Ono Pharmaceutical Co Ltd
TSE:4528
Ono Pharmaceutical Co Ltd
EPS (Diluted)
Ono Pharmaceutical Co Ltd
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Ono Pharmaceutical Co Ltd
TSE:4528
|
EPS (Diluted)
¥157
|
CAGR 3-Years
2%
|
CAGR 5-Years
6%
|
CAGR 10-Years
18%
|
|
|
Takeda Pharmaceutical Co Ltd
TSE:4502
|
EPS (Diluted)
¥131
|
CAGR 3-Years
-22%
|
CAGR 5-Years
73%
|
CAGR 10-Years
7%
|
|
|
Daiichi Sankyo Co Ltd
TSE:4568
|
EPS (Diluted)
¥155
|
CAGR 3-Years
65%
|
CAGR 5-Years
19%
|
CAGR 10-Years
-10%
|
|
|
Otsuka Holdings Co Ltd
TSE:4578
|
EPS (Diluted)
¥633
|
CAGR 3-Years
40%
|
CAGR 5-Years
22%
|
CAGR 10-Years
9%
|
|
|
Chugai Pharmaceutical Co Ltd
TSE:4519
|
EPS (Diluted)
¥249
|
CAGR 3-Years
2%
|
CAGR 5-Years
19%
|
CAGR 10-Years
24%
|
|
|
Astellas Pharma Inc
TSE:4503
|
EPS (Diluted)
¥28
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
-7%
|
|
Ono Pharmaceutical Co Ltd
Glance View
In the bustling city of Osaka, Japan, Ono Pharmaceutical Co., Ltd. stands as a venerable institution with roots tracing back over three centuries. Origination in 1717 as an apothecary, Ono has evolved into a leading biopharmaceutical company renowned for its pioneering work in immunology. They have a rich history of innovation in drug development, marked by the success of their groundbreaking anti-cancer agent, Opdivo. This is a product of their intensive research and development in the field of immune checkpoint inhibitors, a class of drugs that revolutionizes cancer treatment by bolstering the body's natural defenses to combat malignant cells. Ono’s commitment to R&D, underscored by substantial investment, remains its cornerstone, transforming complex scientific concepts into therapeutic products. The essence of Ono Pharmaceutical’s business model rests on its adeptness at translating scientific excellence into commercial success. They operate within two primary segments: pharmaceutical products and clinical testing-related services. The pharmaceutical segment, the larger of the two, is the engine driving revenue through the development and global distribution of prescription drugs, focusing extensively on treatments in the central nervous system, cancer, and infectious diseases. Ono leverages strategic alliances with global pharmaceutical giants, facilitating broader distribution networks and shared research endeavors, thus amplifying their market presence and financial returns. Their strategy encapsulates a cycle of discovery, development, and commercialization, continually striving to deliver innovative medicinal solutions that enhance the quality of life worldwide.
See Also
What is Ono Pharmaceutical Co Ltd's EPS (Diluted)?
EPS (Diluted)
157.6
JPY
Based on the financial report for Dec 31, 2024, Ono Pharmaceutical Co Ltd's EPS (Diluted) amounts to 157.6 JPY.
What is Ono Pharmaceutical Co Ltd's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 10Y
18%
Over the last year, the EPS (Diluted) growth was -41%. The average annual EPS (Diluted) growth rates for Ono Pharmaceutical Co Ltd have been 2% over the past three years , 6% over the past five years , and 18% over the past ten years .
You don't have any saved screeners yet